Treatment of Hereditary C1 Inhibitor Deficiency in Pregnancy and Breastfeeding

Hereditary C1 inhibitor deficiency presents a distinct management challenge when the patient is pregnant or breastfeeding. The physiological changes of pregnancy and the safety requirements of lactation both constrain therapy selection, making a structured, evidence-based approach essential.

Clinical Scenario

This protocol is specifically for patients with hereditary C1 inhibitor deficiency who are currently pregnant or breastfeeding (lactating). These conditions require that therapy be chosen with close attention to maternal and fetal or infant safety.

Treatment Approach

Management in this setting involves a plasma-derived approach, with the choice of specific agent guided by availability and the clinical context of pregnancy or lactation. The full protocol specifies the preferred therapy and the stepwise alternatives — details are in the complete regimen.

Instant Access to Structured Evidence-Based Regimens

References

We recommend plasma-derived C1 inhibitor as the preferred therapy during pregnancy and lactation
SDP may be used when C1-INH is not available and fresh frozen plasma when SDP is not available.

DOI: 10.1111/all.15214

View source ↗